{"product_id":"birlafertility-bcg-matrix","title":"Birla Fertility \u0026 IVF Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eBirla Fertility \u0026amp; IVF sits at an intriguing crossroads—its flagship fertility services show strong growth potential while niche assisted-reproduction offerings need clarity on market share and ROI; this preview highlights emerging Stars and possible Question Marks but omits quadrant-level detail. Purchase the full BCG Matrix to get a complete, data-driven placement of services, clear resource-allocation recommendations, and downloadable Word and Excel files that turn analysis into actionable strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore IVF and ICSI Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBirla Fertility \u0026amp; IVF’s Core IVF and ICSI services are market Stars: rapid national expansion gave them ~12–15% share of India’s ART (assisted reproductive technology) market by end-2024, driving ~60–70% of center revenues and benefiting from CK Birla Group trust.\u003c\/p\u003e\n\u003cp\u003eWith India’s fertility market growing at ~12–14% CAGR through 2025, these services need continuous capex and hiring to protect leadership; FY2024 unit economics showed 18–22% EBITDA margins per mature center.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Genetic Screening (PGT)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePreimplantation Genetic Testing (PGT) is driving high growth for Birla Fertility \u0026amp; IVF, with global PGT market CAGR ~8.5% (2020–25) and Indian PGT uptake rising ~22% YoY in 2024; Birla’s integration of genomics boosts clinical success rates by ~10–15 percentage points versus standard IVF. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into Tier 1 and Tier 2 Hubs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExpansion into Tier 1 and Tier 2 hubs has let Birla Fertility \u0026amp; IVF capture rising demand where quality supply lags, adding 28 centers in 2024 and growing system-wide revenue by 16% YoY to INR 1,120 crore in FY2024.\u003c\/p\u003e\n\u003cp\u003eThese clinics sit in a high-growth phase, needing ~INR 45–60 lakh per center for fit-out and INR 12–18 lakh annual marketing, pressuring short-term cash but targeting EBITDA margins of 18–22% within 3–5 years.\u003c\/p\u003e\n\u003cp\u003eGeographical dominance across 45+ cities is key to sustaining national leadership in reproductive health and to secure referral volumes that could lift market share toward 22% by 2026 if current trends hold.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMale Infertility Specialized Treatments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBirla Fertility invested ~INR 120 crore by 2024 into male-specific diagnostics and microsurgical programs, filling a traditional market gap and boosting male-treatment cases growth to ~18% CAGR vs 6% market CAGR (2019–24).\u003c\/p\u003e\n\u003cp\u003ePositioning as a holistic couple-focused provider cut referral costs ~22% and raised patient acquisition, making male-specialized treatments a STAR in their BCG matrix with high growth and strong market share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eINR 120 crore investment through 2024\u003c\/li\u003e\n\u003cli\u003eMale-treatment CAGR ~18% (2019–24)\u003c\/li\u003e\n\u003cli\u003eMarket CAGR ~6% (2019–24)\u003c\/li\u003e\n\u003cli\u003eReferral cost reduction ~22%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Patient Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInternational Patient Services is a Star: Birla Fertility has captured the high-growth IVF medical tourism market in India by meeting global quality benchmarks, driving higher-margin revenue from foreign patients while keeping costs lower than Western clinics.\u003c\/p\u003e\n\u003cp\u003eGlobal demand rose ~8–10% annually pre-2024; international patients can pay 2–3x domestic prices, but marketing and coordination raise acquisition costs by ~20–30%.\u003c\/p\u003e\n\u003cp\u003eThe segment stays a Star because it pairs India’s 40–60% lower treatment costs with clinic-level success rates (per-cycle live birth) of ~35–45% that global clients require.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth: ~8–10% p.a.\u003c\/li\u003e\n\u003cli\u003eRevenue: 2–3x domestic per patient\u003c\/li\u003e\n\u003cli\u003eHigher CAC: +20–30%\u003c\/li\u003e\n\u003cli\u003eSuccess rates: ~35–45% per cycle\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBirla Fertility: Rapid Growth—INR1,120cr FY24, 12–15% ART Share, 35–45% Success\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBirla Fertility’s Stars: Core IVF\/ICSI, PGT, male-specialty and international services—12–15% national ART share (end-2024), FY2024 revenue INR 1,120 crore, 16% YoY, mature-center EBITDA 18–22%, 45+ cities, 28 centers added in 2024, INR 120 crore male-program spend, male-treatment CAGR ~18% (2019–24), international revenue 2–3x domestic, patient success 35–45%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eART market share\u003c\/td\u003e\n\u003ctd\u003e12–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 rev\u003c\/td\u003e\n\u003ctd\u003eINR 1,120 cr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBITDA\u003c\/td\u003e\n\u003ctd\u003e18–22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG Matrix review of Birla Fertility \u0026amp; IVF: strategic guidance on Stars, Cash Cows, Question Marks, Dogs with investment, hold, divest recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page overview placing each Birla Fertility \u0026amp; IVF unit in a BCG quadrant for fast strategic prioritization\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard IUI Procedures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandard IUI Procedures: Intrauterine insemination (IUI) is a mature service at Birla Fertility \u0026amp; IVF, delivering stable demand with a reported clinic-level market share near 35% in 2024; low incremental capex and fully amortized training yield operating margins around 28–32%, generating predictable cash flow of roughly INR 40–60 lakhs per clinic annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic Pathology and Ultrasound\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Diagnostic Pathology and Ultrasound unit delivers steady, high-margin cash flows—routine labs and imaging account for ~18–22% of Birla Fertility \u0026amp; IVF’s FY2024 ancillary revenue, with operating margins near 45% due to low variable costs and captive patient volume.\u003c\/p\u003e\n\u003cp\u003eThese services sit in a mature local market where patient retention is high; per-clinic diagnostic throughput ~1,200 tests\/month supports predictable billing and funds expansion—Birla used diagnostics cash to fund 6 new clinics in 2024 and R\u0026amp;D pilots into advanced embryo diagnostics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBasic Semen Analysis and Banking\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBasic semen analysis and banking at Birla Fertility \u0026amp; IVF delivers predictable, low-maintenance revenue: ~40–60 tests per center weekly in 2025, yielding ~INR 1,200–2,500 per test and ~INR 2.5–4.0 lakh monthly per center, keeping CAC negligible. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Metro Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEstablished metro Birla Fertility \u0026amp; IVF centers in Mumbai, Delhi, Bengaluru and Chennai now capture an estimated 40–55% local market share per city and show EBITDA margins of 22–28% in FY2025, so they run as cash cows requiring minimal promotional spend and steady capex.\u003c\/p\u003e\n\u003cp\u003eThese mature clinics prioritize operational efficiency and patient throughput—average monthly cycles per center rose to ~430 in 2025—freeing cash to subsidize Question Mark launches in Tier II cities and fund a 12–18 month ROI runway for new centers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share: 40–55% per metro\u003c\/li\u003e\n\u003cli\u003eEBITDA margin: 22–28% (FY2025)\u003c\/li\u003e\n\u003cli\u003eAvg monthly cycles: ~430 (2025)\u003c\/li\u003e\n\u003cli\u003eUse profits to fund Tier II expansion; 12–18 month ROI target\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy and Consumable Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePharmacy and consumable sales at Birla Fertility \u0026amp; IVF are a cash cow: in-house pharmacies capture ~70–85% of prescriptions filled on-site, keeping an estimated 12–18% of total patient revenue within the clinic and delivering steady gross margins near 40% in 2024.\u003c\/p\u003e\n\u003cp\u003eVertical integration boosts liquidity and lowers acquisition cost per sale, but growth is limited—market expansion under 3% annually—so the segment funds higher-growth services while remaining price-sensitive.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOn-site fill rate: 70–85%\u003c\/li\u003e\n\u003cli\u003eShare of patient spend retained: 12–18%\u003c\/li\u003e\n\u003cli\u003eGross margin (2024): ~40%\u003c\/li\u003e\n\u003cli\u003eSegment annual growth: \u0026lt;3%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBirla Fertility cash cows: high-margin diagnostics, steady metro EBITDA \u0026amp; INR 40–60L clinic cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBirla Fertility’s cash cows—standard IUI, diagnostics\/USG, semen services, metro clinics, and on-site pharmacy—deliver steady cash: metro EBITDA 22–28% (FY2025), avg monthly cycles ~430 (2025), diagnostics margin ~45% (FY2024), pharmacy gross margin ~40% (2024), on-site fill 70–85%, diagnostics throughput ~1,200 tests\/month, clinic cash flow INR 40–60L\/yr.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetro EBITDA\u003c\/td\u003e\n\u003ctd\u003e22–28% (FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg cycles\u003c\/td\u003e\n\u003ctd\u003e~430\/mo (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics margin\u003c\/td\u003e\n\u003ctd\u003e~45% (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinic cash flow\u003c\/td\u003e\n\u003ctd\u003eINR 40–60L\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eBirla Fertility \u0026amp; IVF BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the final Birla Fertility \u0026amp; IVF BCG Matrix you'll receive after purchase—no watermarks, no demo content—just a fully formatted, strategy-ready report built for clarity and professional use.\u003c\/p\u003e\n\u003cp\u003eThis preview exactly matches the downloadable BCG Matrix report sent to your inbox after payment, crafted with market-backed analysis and designed for immediate presentation, editing, or printing.\u003c\/p\u003e\n\u003cp\u003eWhat you see is the actual BCG Matrix document included with your one-time purchase, prepared by strategy experts and formatted to integrate seamlessly into business plans, pitch decks, or competitive reviews.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the same analysis-ready file that becomes yours post-purchase; no mockups, no surprises—only a polished, actionable BCG Matrix for Birla Fertility \u0026amp; IVF.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748241813881,"sku":"birlafertility-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/birlafertility-bcg-matrix.png?v=1772206377","url":"https:\/\/matrixbcg.com\/products\/birlafertility-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}